After a number of positive referals, Sound Bioventures decided to hire Andulf Advokater with Anders Apell and Ulf Edebrink, as their legal representatives. Anders and Ulf where part of founding Andulf Advokater, back in 2004, and specializes in private equity, venture capital and real estate fund formation. Johan Kördel commented: “Others had told us that Anders and Ulf have superb and strategic legal minds – Boy can we underwrite that! We are so happy to have them on our side. Experienced and efficient – they cut to the chase”
Sound Bioventures Works with Andulf Advokater
Beyond fundraising: how do venture capitals build early-stage biotechs?
It’s no secret that venture capital is what drives early-stage drug development in the biotech industry. But beyond being a simple source of cash to spend on research, some VCs play a significant role in building the company with its founders. To better understand the dynamic between biotech startups and VCs, we talked to Johan […]
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m ...
Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.
Safety and Efficacy Results Are Expected in Second Half of 2024 Evaluating AX-158, a First in Class Nck Blocker, Shifting the Paradigm of Autoimmune Disease Treatment. AX-158 Has Broad Potential to Treat Many Autoimmune Diseases without Causing Immunosuppression. Autoimmune Diseases Remain a Significant Unmet Medical Need, affecting Millions ...
VC Investing in Clinical Stage Biotherapeutics Companies in Europe and the U.S.
In this episode of Engaging Alternatives Spotlight, Elana Margulies-Snyderman, Director, Publications, EisnerAmper, speaks with Bibhash Mukhopadhyay, Managing Partner, Sound Bioventures, a venture capital fund that invests in about-to-be clinical or clinical stage private companies in Europe and the U.S. developing therapies in specialty therapeuti ...